NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (Nasdaq and TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces completion of the pivotal Phase II/III clinical trial in Europe and Canada of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or Inherited Emphysema). Kamada expects to report top-line results from this study in the first quarter of 2014. The multicenter random
Reported by Business Wire 11 hours ago.
↧